Human Papillomavirus Vaccination Coverage Estimates Among the Primary Target Cohort (9-14-Year-Old Girls) in the World (2010-2024).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Video-based interventions to promote HPV vaccination among individuals aged 9 to 26: a systematic review and meta-analysis.BMC public health · 2026
   Pooled it
2. Evolving Clinicopathological Characteristics of Women with Locally Advanced Cervical Cancer Treated with Definitive Chemoradiation Before and After Implementation of Organized Cervical Cancer Screening in Serbia.Cancers · 2026
   Article
3. Knowledge and Perceptions of Human Papillomavirus Infection and Vaccination Among Adolescents in French Rural Family Homes: A Mixed-Methods Study.Vaccines · 2026
   Article
4. Human Papillomavirus Vaccine Intent and Associated Factors Among the Unvaccinated University Freshmen in the Largest University Town in China.Vaccines · 2026
   Article
5. Pakistan's 2025 HPV Vaccine Phase I Rollout: Community Response, Implementation Challenges & Way Forward.Vaccines · 2026
   Article
6. Cutaneous-Tropism Viruses: Unraveling Pathogenetic Mechanisms and Immunoprophylactic Strategies.Life (Basel, Switzerland) · 2026
   Review
7. Gender-neutral human papillomavirus vaccination: an equitable and cost-effective public health investment.Frontiers in public health · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as